Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avdoralimab in Bullous Pemphigoid
NCT04563923Phase 2Completed
- Sponsor
- Centre Hospitalier Universitaire de Nice
- Start
- Oct 2020
- Primary completion
- Apr 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of avdoralimab in Bullous Pemphigoid (BP) (2 arms), sponsored by Centre Hospitalier Universitaire de Nice. Primary endpoint: Complete Clinical Remission at 3 months. Started Oct 2020; status: completed.
02
Drugs
avdoralimab
03
Conditions
Bullous Pemphigoid (BP)
Beyond the preview
Go deeper on NCT04563923.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04563923.